期刊文献+

氨基胍对糖基化终产物干预后人肾系膜细胞fractalkine表达的影响 被引量:3

Effect of Aminoguanidine on Fractalkine Expression of AGE-Treated Human Renal Mesangial Cells
下载PDF
导出
摘要 目的观察氨基胍(AG)对体外制备的糖基化终产物(AGEs)诱导的人肾系膜细胞(HRMC)趋化因子fractalkine表达的影响。方法分别给予无血清的DMEM培养基、牛血清清蛋白(BSA)、糖基化终产物-牛血清清蛋白(AGE-BSA)干预HRMC,以及不同浓度AG与AGE-BSA共同干预HRMC 24 h;采用RT-PCR和Western-blot法分别检测HRMC fractalkine mRNA和蛋白表达。结果与DMEM、BSA组相比,AGE-BSA明显升高HRMC frac-talkine mRNA和蛋白表达(P<0.05),AG以浓度依赖的方式下调HRMC fractalkine mRNA和蛋白表达(P<0.05)。结论 AG可能通过拮抗AGEs对fractalkine表达的增加作用而发挥其肾脏保护作用。 Objective To investigate the effect of aminoguanidine (AG) on fractalkine expression of advanced glyeo- sylation end products (AGEs) treated human renal mesangial cells (HRMC) . Methods HRMC were incubated with DMEM, bovine serum albumin (BSA) and AGE - BSA respectively, as well as the combination of different concentrations of AG and AGE - BSA for 24 hours. The mRNA and protein expressions of fractalkine in HRMC were tested by RT - PCR and Westernblot respec- tively. Results The expression levels of fractalkine mRNA and protein in HRMC treated with AGE - BSA were significantly high- er than those in HRMC treated with DMEM and BSA ( P 〈 0. 05 ) . The down - regulation of mRNA and protein in HRMC by AG was concentration dependent (P 〈 0. 05 ) . Conclusion AG might play its renal protection role via the attenuation of the up - regulation of fraetalkine by AGEs.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第27期3146-3148,共3页 Chinese General Practice
关键词 氨基胍 糖尿病肾病 糖基化终产物 FRACTALKINE Aminoguanidine Diabetic nephropathy Advanced glycosylation end products Fraetalkine
  • 相关文献

参考文献11

二级参考文献60

共引文献22

同被引文献47

  • 1张文顺,石岩.中药复方益糖康对DN模型大鼠肾脏组织中AGEs、RAGEs影响的实验研究[J].中国生化药物杂志,2014,34(2):45-47. 被引量:14
  • 2Sekido H, Suzuki T, Jomori T, et al. Reduced cell replication and in- duction of apoptosis by advanced glycation end products in rat Schwann cells [J]. Biochem Bioph Res Co, 2004, 320 (1) : 241 -248.
  • 3Stitt AW. AGEs and diabetic retinopathy [ J ]. Invest Ophthalmol Vis Sci, 2010, 51 (10): 4867-4874.
  • 4Barlovic DP, Soro - Paavonen A, Jandeleit - Dahm KA. RAGE biolo- gy, atherosclerosis and diabetes [ J ]. Clin Sci ( Lond ), 2011, 121 (2) : 43 -55.
  • 5Bos DC, de Ranitz - Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review [J]. Diabetes Technol The, 2011, 13 (7) : 773 - 779.
  • 6Misur I, Zarkovic K, Barada A, et al. Advanced glycation endprod- ucts in peripheral nerve in type 2 diabetes with neuropathy [ J ]. Acta Diabetol, 2004, 41 (4): 158-166.
  • 7Wada R, Nishizawa Y, Yagihashi N, et al. Effects of OPB -9195, anti -glycation agent, on experimental diabetic neuropathy [ J ]. Eur J Clin Invest, 2001, 31 (6) : 513 -520.
  • 8Magnaghi V, Procacci P, Tata AM. Novel pharmacological approaches to Schwann cells as neuroprotective agents for peripheral nerve regenera- tion [J]. Int Rev Neurobiol, 2009, 87:295-315.
  • 9Lehmann HC, Hoke A. Schwann cells as a therapeutic target for pe- ripheral neuropathies [J]. CNS Neurol Disord Drug Targets, 2010, 9 (6): 801-806.
  • 10殷汉,孙子林,王尧.羧甲基赖氨酸和可溶性糖基化终产物受体水平与2型糖尿病冠状动脉钙化相关性研究[J].中国全科医学,2011,14(4):388-390. 被引量:6

引证文献3

二级引证文献173

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部